CMS assigns J‑code
CMS assigned a permanent, product‑specific J‑code for YARTEMLEA (narsoplimab‑wuug), a decision reported to facilitate claims and reimbursement. (biospace.com) The BioSpace release frames the move as intended to simplify billing and claims processing for that therapy. (biospace.com)
The Centers for Medicare & Medicaid Services assigned YARTEMLEA a permanent billing code, giving the rare-disease drug its own identifier for reimbursement starting July 1, 2026. (investor.omeros.com) Omeros said the code is J1289 and applies to YARTEMLEA, the brand name for narsoplimab-wuug. The company disclosed the assignment on April 16, 2026. (investor.omeros.com) A J-code is part of the Healthcare Common Procedure Coding System, the billing language Medicare and many insurers use for physician-administered drugs. CMS billing guidance says hospitals often use unclassified codes before a product-specific code is assigned. (cms.gov) That means the change is less about how the drug works than how providers get paid for using it. Omeros said a product-specific code can simplify claims processing for Medicare and commercial insurance. (investor.omeros.com) YARTEMLEA itself is a treatment for transplant-associated thrombotic microangiopathy, or TA-TMA, a serious complication that can follow a stem cell transplant. The Food and Drug Administration approved it in January 2026 as the first approved treatment for adults and children age 2 and older with that condition. (fda.gov) The drug is given by intravenous infusion and is classified as a MASP-2 inhibitor, meaning it blocks part of the complement system, an immune pathway involved in the disease process. The FDA label lists YARTEMLEA as an intravenous injection with initial U.S. approval in 2025. (accessdata.fda.gov) For hospitals and infusion providers, a permanent code can reduce the back-and-forth that comes with miscellaneous billing entries and manual claim review. CMS uses separate coding pathways for new drugs before and after a product-specific Healthcare Common Procedure Coding System code is in place. (cms.gov) Omeros tied the coding change directly to access, saying faster and more predictable reimbursement can help patients start treatment without administrative delays. The practical test comes on July 1, when J1289 becomes the code providers can put on claims. (investor.omeros.com)
